Meredith Hay, PhD 

Dr. Hay is internationally known for her research in brain regulation of blood pressure and the central effects of Ang-(1-7) to inhibit brain inflammation and reactive oxygen production. She is a co-inventor on a number of patents for Ang-(1-7) and related peptides as brain protectant therapies. Dr. Hay has been an actively NIH funded researcher for over 35 years and has extensive experience in successfully leading not only her own research team but also in leading and building large multi-institutional research programs as evidenced by her leadership as past Vice President for Research at the University of Iowa and as past Executive Vice President and Provost of the University of Arizona.

Dr. Hay is also President and founder of a Tucson biotechnology company, ProNeurogen, Inc. ProNeurogen is a preclinical and clinical stage biopharmaceutical company developing novel peptide-based therapeutics to treat vascular dementia. Dr. Hay and ProNeurogen are collaborating with physicians and scientists at the University of Arizona College of Medicine, the Evelyn F. McKnight Brain Institute, BIO5 Institute and Banner Alzheimer’s Institute to advance these peptides through FDA Phase II clinical trials. The goal of these studies is to reduce or prevent memory loss related to systemic inflammatory disease.